MAPT and supranuclear palsy, progressive, 1: Furthermore, while tau biomarkers show promise in distinguishing between primary 4R and 3R tauopathies [28], data remain limited regarding their ability to differentiate between specific 4R tauopathies, such as PSP and CBD [28,29].